SARCLISA® (isatuximab-irfc) | A Targeted Immunotherapy
WEBSARCLISA is a targeted monoclonal antibody given with other medicines for adults with previously treated multiple myeloma. See full Safety & Prescribing Info.
FDA approves isatuximab-irfc for multiple myeloma | FDA
WEBOn March 31, 2021, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, sanofi-aventis U.S. LLC) in combination with carfilzomib and dexamethasone, for the treatment of adult...
FDA Approves New Therapy for Patients with Previously Treated …
WEBToday, the U.S. Food and Drug Administration approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who...
Isatuximab - Wikipedia
WEBMechanism of action. Metabolism and toxicity. Toxicity. Pregnancy. Indications. Efficacy and side effects. Side effects. Effects on animals. Names. See also. References. External links. Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma. [6] [4]
Sarclisa® (isatuximab-irfc) Phase 3 trial met primary endpoint of ...
WEBDec 7, 2023 · Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Sarclisa: Uses, Dosage, Side Effects, Warnings - Drugs.com
WEBSep 4, 2023 · Sarclisa is a prescription medicine used in combination with: the medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
FDA approves Sarclisa® (isatuximab) in combination with ... - Sanofi
WEBMarch 31, 2021. Download PDF. FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Sarclisa regimen reduced risk of disease progression or death by 45% compared to standard of care in patients who had relapsed after one to three prior therapies.
SARCLISA® (isatuximab-irfc) | Patient & Caregiver Resources
WEBPATIENT AND CAREGIVER RESOURCES. Get information and helpful resources about SARCLISA and multiple myeloma. Choose from the options below to get downloadable resources for patients, helpful information for caregivers, and information about multiple myeloma education and support networks. Resources for patients. A Guide to SARCLISA.
Sarclisa | European Medicines Agency
WEBSarclisa is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow). It is given: together with the medicines pomalidomide and dexamethasone to treat adults who have received at least two previous treatments for their cancer, including lenalidomide and a proteasome inhibitor, and whose cancer has worsened since …
Press Release: Sarclisa® (isatuximab) Phase 3 trial met ... - Sanofi
WEBDec 7, 2006 · Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Skip to content